What Regorafenib Treats: Main Uses and Benefits

Regorafenib is generally used to manage specific advanced or metastatic cancers, playing a role in symptomatic management after other standard treatments may have been exhausted. It is an agent applied in the context of malignancy, addressing symptoms related to systemic imbalance caused by the disease itself.

The medication is commonly used to help manage late-stage cancers, specifically metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC). It is applied when these conditions marked by increased physiological stress have progressed despite prior systemic therapies. The medication is considered relevant as a subsequent-line treatment option for adult patients with resistant or refractory disease.

The primary therapeutic effect is focused on achieving disease stabilization. This therapeutic effect generally contributes to the management of functional stability and disease progression (clinical outcomes). By helping to stabilize the malignancy, Regorafenib may be part of symptomatic management to help ease the overall symptom load associated with cancer progression.

Quick Fact: Relief for Advanced Cancer Symptoms

Who Can and Cannot Use Regorafenib?

This information is based strictly on eligibility criteria found in official government regulatory documents.

Contraindications and Restrictions

Regorafenib is formally contraindicated in patients with a known hypersensitivity (allergic reaction) to the active substance or any component of the formulation.

Use is not recommended for patients who have severe hepatic impairment (Child-Pugh C), as the pharmacokinetics have not been established in this population and potential for increased exposure exists.

Adult Patients (18 years and older) are the eligible population for the approved indications. For patients with moderate hepatic impairment (Child-Pugh B), close safety monitoring is required, but no dose adjustment is necessary for patients with any degree of renal impairment.

Interaction Profile Summary

Regorafenib's interaction profile is primarily governed by its metabolism and its effects on drug transporters. The primary metabolic pathways for regorafenib are the enzyme CYP3A4 and the conjugating enzyme UGT1A9.

Official regulatory labeling dictates that co-administration with strong inducers (e.g., rifampin, phenytoin, St. John's Wort) or strong inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) of CYP3A4 is restricted to prevent significant alterations in regorafenib exposure. Products that are substrates for the transport protein BCRP (e.g., methotrexate, fluvastatin, atorvastatin) require close monitoring due to regorafenib's inhibitory effect, which can elevate the substrate's plasma concentration.

Regorafenib acts as an oral multi-kinase inhibitor, exerting its pharmacodynamic effect by concurrently disrupting three distinct biological pathways that support tumor function. The primary mechanism is the inhibition of angiogenesis, achieved through the blockade of receptors like VEGFR1, VEGFR2, and VEGFR3, along with PDGFRs and TIE2. This action restricts the signaling required for endothelial cell function, resulting in the physiological restriction of neovascularization and nutrient delivery to the tissue. Secondly, the drug directly interferes with oncogenic signaling by inhibiting kinases such as KIT, RET, RAF-1, and BRAF. This disruption of the MAPK pathway induces apoptosis and achieves antiproliferation in the cancer cells. Lastly, Regorafenib modulates the tumor's microenvironment by inhibiting CSF1R, reducing the function of Tumor-Associated Macrophages ( TAMs)** and thereby creating a less immunosuppressive milieu. The overall multi-target inhibition is sustained by the activity of the M-2 and M-5 active metabolites.

Official Administration and Dosing Guidelines

Regorafenib is an oral medication, administered as a 40 mg film-coated tablet. The primary instruction for use is centered on a fixed, 28-day cyclic regimen.

Standard Dosing and Schedule

The recommended starting dose is 160 mg (four 40 mg tablets) taken once daily. This daily dose is administered for the first 21 days of the 28-day cycle, followed by a mandated 7-day treatment break. Treatment is continued following this cyclic pattern until a determination of disease progression or unacceptable tolerability. For dose adjustment, the dose may be reduced in 40 mg steps, with the lowest recommended daily dose being 80 mg.

Administration Conditions

• Food Requirement: The tablets must be swallowed whole with water after a low-fat meal. A low-fat meal is specifically defined as containing less than 600 calories and less than 30% fat.
• Timing: To maintain consistent levels, the medicine should be taken at the same time each day.
• Missed Dose: If a daily dose is missed, it should be taken on the same day as soon as it is remembered. Patients are instructed not to take two doses on the same day to compensate for a missed dose from the previous day.

Population-Specific Use

No dose adjustment is required based on age or for patients with mild to moderate renal or hepatic impairment (Child-Pugh A or B). Use is not recommended in patients with severe hepatic impairment (Child-Pugh C) as this population has not been adequately studied.

Evidence for use in Metastatic Colorectal Cancer (mCRC)

Research for mCRC was evaluated in adult patients whose disease had progressed despite receiving standard systemic therapies. Large Phase III Randomized Controlled Trials (RCTs) compared Regorafenib against a placebo. The primary outcomes monitored included Overall Survival (OS) and Progression-Free Survival (PFS). The studies reported measurements of OS and PFS that differed between the Regorafenib and placebo groups. The reported timeframe of the findings is measured in months, reflecting a common pattern in research studying conditions marked by functional limitations. The existing data mainly applies only to the populations studied—specifically, those with good functional status.

Evidence for use in Gastrointestinal Stromal Tumors (GIST)

For advanced GIST, a pivotal Phase III RCT (the GRID study) was evaluated in adult patients whose disease had progressed following prior treatment with two other common targeted therapies. The primary outcome research examined was Progression-Free Survival (PFS). The studies reported measurements of PFS that were recorded over a longer period in the Regorafenib group compared to the placebo group. The trial protocol allowed patients on placebo to cross over to receive Regorafenib upon progression. Due to this allowance, it is not yet clear whether the measurements of Overall Survival were associated with the initial randomization.

Evidence for use in Hepatocellular Carcinoma (HCC)

Regorafenib was evaluated in a pivotal Phase III RCT (the RESORCE study) for the treatment of HCC in adult patients whose disease had progressed after prior treatment with sorafenib. The core trial had specific entry requirements, allowing only patients with preserved liver function (Child-Pugh A) to participate. The main goal research explored was Overall Survival (OS). The studies reported measurements of OS and PFS that were recorded over a longer period for the Regorafenib group compared to the placebo group.

Long-Term Studies and Research Gaps

The primary evidence comes from studies observing responses over defined time intervals in the key RCTs. Follow-up durations were limited in the initial trials, though some real-world observational studies have been conducted. Research highlights areas where data for certain groups remain insufficient, such as patients with poor functional status or impaired liver function (Child-Pugh B or C). Additionally, the trial data described patterns where managing dose-related events often resulted in patients requiring dose adjustments. Long-term effects are not fully established outside of retrospective observation.

How to Store and Dispose of Regorafenib

Regorafenib tablets must be stored strictly according to official regulatory requirements to ensure stability. The medicine must be kept at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C), and must be protected from moisture. Storage must occur in the original container.

A critical stability rule is that any remaining tablets in an opened bottle must be discarded 7 weeks (49 days) after the date the bottle was first opened.

For safety, the container must be stored out of the sight and reach of children.

Disposal of unused or expired tablets must be done according to local requirements and is prohibited from being discarded in wastewater or household trash.